Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome
- PMID: 34824956
- PMCID: PMC8582768
- DOI: 10.9740/mhc.2021.11.311
Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome
Abstract
Antipsychotic medications increase the risk of metabolic syndrome, which then increases the risk of atherosclerotic cardiovascular disease and premature death. Routinely monitoring for signs of metabolic syndrome in patients taking antipsychotics allows for early detection and intervention. Psychiatric pharmacists can improve patient care through metabolic syndrome monitoring and recommendation of appropriate interventions. Monitoring for the metabolic adverse effects of antipsychotics, management of weight gain, and management of lipids and blood pressure are explored through 2 patient cases.
Keywords: antipsychotics; blood pressure; lipids; metabolic syndrome; psychiatric pharmacist; weight.
© 2021 CPNP. The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists.
Conflict of interest statement
Disclosures: I have nothing personal to disclose. Psychopharmacology Pearls are review articles intended to highlight both the evidence base available and/or controversial areas of clinical care for psychiatric and neurologic conditions as well as strategies of clinical decision-making used by expert clinicians. As pearls, articles reflect the views and practice of each author as substantiated with evidence-based facts as well as opinion and experience. Articles are edited by members of the Psychopharmacology Pearls Editorial Board as well as peer reviewed by MHC reviewers. This article was developed as part of the 2021 Psychopharmacology Pearls product for BCPP recertification credit. The course information and testing center is at https://cpnp.org/459431.
References
-
- Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295–301. 10.1016/S2215-0366(17)30078-0 PubMed PMID: 28237639. - DOI - PubMed
-
- Westman J, Eriksson SV, Gissler M, Hällgren J, Prieto ML, Bobo WV, et al. Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study. Epidemiol Psychiatr Sci. 2018;27(5):519–27. 10.1017/S2045796017000166 PubMed PMID: 28580898 PubMed Central PMCID: PMC6137375. - DOI - PMC - PubMed
-
- Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172–81. 10.1001/jamapsychiatry.2015.1737 PubMed PMID: 26509694. - DOI - PubMed
-
- Peet M. Diet, diabetes and schizophrenia: review and hypothesis. Br J Psychiatry Suppl. 2004;47:S102–5. 10.1192/bjp.184.47.s102 PubMed PMID: 15056602. - DOI - PubMed
-
- de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2-3):135–57. 10.1016/j.schres.2005.02.010 PubMed PMID: 15949648. - DOI - PubMed
LinkOut - more resources
Full Text Sources